Irradiation + Chemotherapy for Acute Myeloid Leukemia

This trial tests a combination of treatments to help older patients with acute myeloid leukemia (a type of blood cancer) or high-risk myelodysplastic syndrome (a blood disorder) who have not responded to previous treatments or whose condition has returned. The trial combines a special type of radiation called total marrow and lymphoid irradiation (TMLI) with the chemotherapy drugs fludarabine phosphate and melphalan before a stem cell transplant from a donor. The goal is to determine if this treatment plan can be safer and more effective in preparing the body for new, healthy blood cells. Suitable candidates for this trial are those 50 years or older with these conditions who have access to a matching stem cell donor. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial protocol does not specify if you need to stop taking your current medications. However, it mentions that certain low-dose or maintenance chemotherapy drugs are allowed close to the start of the trial. It's best to discuss your specific medications with the trial team.

Research has shown that total marrow and lymphoid irradiation (TMLI) combined with the chemotherapy drugs fludarabine and melphalan is generally well-tolerated by patients. TMLI targets specific areas such as the bone marrow and lymph nodes, potentially reducing side effects compared to traditional radiation that affects more of the body.

Fludarabine and melphalan have been studied for their role in preparing patients for stem cell transplants. This combination can be suitable, particularly for patients who may not tolerate stronger treatments. While side effects can occur, these drugs have been used in similar situations with generally manageable safety.

Researchers are excited about this treatment for acute myeloid leukemia (AML) because it combines total marrow and lymphoid irradiation (TMLI) with fludarabine and melphalan, offering a potentially more targeted approach than traditional chemotherapy regimens. Unlike standard treatments that often rely solely on drugs, TMLI aims to precisely target the bone marrow and lymphoid tissues, which could lead to better outcomes and fewer side effects. Additionally, the use of allogeneic peripheral blood stem cell transplantation (PBSC-HCT) on day 0 is intended to replace diseased cells with healthy ones, potentially offering a more durable solution to fighting AML. This combination of therapies and the precise targeting strategy are what make this treatment approach particularly promising.

In this trial, participants will receive a combination of fludarabine, melphalan, and total marrow and lymphoid irradiation (TMLI) to treat acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome. Studies have shown that this method targets cancer cells while preparing the body for a stem cell transplant. Fludarabine and melphalan damage the DNA of cancer cells, stopping their growth. TMLI, a type of focused radiation, aims to reduce side effects while enhancing treatment effectiveness. For patients who have not responded to previous treatments, this combination has shown promise in improving outcomes and survival rates.¹²⁴⁶⁷